Monday, 22 April 2024

Portfolio Management and Pipeline Optimization for Generics (15th Edition) conference to unravel global generic pharma market opportunities

08 August 2022 | News

Aims to facilitate partnerships and alliances among diversified global and domestic generic pharmaceutical markets and to capitalize on the investment

Pharmaceutical companies need to ensure they have a competitive edge in the market while adapting to evolving industry best practices that advance product selection and portfolio management. From developing and selecting products that will optimize a portfolio, to engaging in potential partnerships with a CMO/CDMOs to improve engagement and increase ROI, these generic pharmaceutical companies need to implement actionable tools and strategies that can streamline these changes efficiently and quickly.

Addressing all the above, the premier Portfolio Management and Pipeline Optimization for Generics, 15th Edition conference will feature a variety of content-rich presentations on portfolio optimization, product selection, portfolio value, partnership and alliance management, and forecasting for future projects, and capitalizing on new opportunities to drive business growth. During the conference, the delegates and players in the generic pharma space will discuss on how to navigate the world space to acquire their major supplies in a timely manner to make profitable deals by building value-added alliances and partnerships. The forum will also help in understanding market competitiveness, challenges in entering new markets, technologies, and branded and complex formulations.

Benefits of attending:

  • Consider key aspects for ‘Market Pricing’ while working on the business case of the product and impact on the balance sheet
  • Pioneer business strategy through optimal alliances and partnerships via efficient and effective planning and processes
  • Foster collaborative and competent partnerships to support and deliver on timelines
  • Capitalize on the right product mix to find the right cost structure by using realistic timelines
  • Deliver organizational objectives and goals that highlight value of program alignment, importance and relevance
  • Align business terms to ensure and take advantage of all available opportunities and remain competitive while navigating an evolving market

Best practices and case studies from:

  • Kevin Ostrander, Vice President, Business Development, Apiject
  • Maha Mehanna, Associate Director, Portfolio Development, XGen Pharmaceuticals
  • Alpesh Patel, Head- Strategic International Expansion & Senior Vice President -Global Regulatory Affairs, BTI & SETE, Amneal Pharmaceuticals
  • Michael Roy, Director - International Sales and International Business Development of Generics Business, Mallinckrodt Pharmaceuticals
  • Ayushman Hazarika, Director Finance, Novartis Pharmaceuticals
  • Modestus Obochi, Executive Vice President, Strategy & Business Development, Phlow Corporation

For more information and discounts available for Biospectrum Asia members, please contact: Mr. Ayis Panayi, Digital Media and PR Marketing Executive at or visit

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account